<DOC>
	<DOC>NCT00968851</DOC>
	<brief_summary>This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will be evaluated.</brief_summary>
	<brief_title>Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled, Phase 2 safety/efficacy study in which two dose levels of EVP-6124 will be evaluated. Eligible for enrollment will be patients who meet clinical criteria for schizophrenia and who are taking chronic atypical anti-psychotic medication at a stable dose. This study will therefore evaluate the effects of EVP-6124 when administered concomitantly with anti-psychotic medication. Patients will be randomized to one of the following groups: 0.3 mg or 1.0 mg EVP-6124, or placebo. Seventy-five patients per group. Study drug will be supplied as capsules and will be orally administered once daily for a total of 84 days.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>Subjects who meet clinical criteria for schizophrenia or schizoaffective disorder utilizing the structured clinical interview (SCI) Must be treated with a second generation antipsychotic drug other than clozapine at a stable dose for at least 4 weeks and must have been on that drug and clinically stable for at least 8 weeks Must have no more than "moderate" severity rating for negative symptoms: BPRS item ≤4 A minimal level of extrapyramidal symptoms (EPS); SimpsonAngus Scale total score ≤6 A minimal level of depression; Calgary Depression Scale total score ≤10 Must have a general health status acceptable for participation in a 12week clinical trial Fluency (oral and written) in the language in which the standardized tests will be administered If a smoker, the ability to refrain from smoking for at least 30 minutes prior to any cognitive testing General Insufficiently controlled diabetes mellitus in the judgment of the investigator Malignant tumor within the last 5 years with the exception of squamous and basal cell carcinoma or cervical carcinoma it situ Pregnancy, nursing, (or if fertile female) not willing to utilize birth control measures during study Unstable medical condition that is clinically significant in the judgment of the investigator: major organ system dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Central nervous System Diseases</keyword>
	<keyword>Cognition</keyword>
</DOC>